Crenezumab Phase II cognition data in Alzheimer’s disease presented

21-Jul-2014 - Switzerland

AC Immune announced the presentation of data from two phase II studies investigating whether crenezumab (anti beta-amyloid antibody) can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease (AD) by its partner Genentech, a member of the Roche Group. The larger proof of concept study, known as ABBY, showed differences from placebo favoring crenezumab in the rate of cognitive decline, especially in milder patients. Similar effects of favoring crenezumab in milder patients were observed in BLAZE, a smaller biomarker study. Although generally not reaching statistical significance, changes in both studies were consistent over time, providing evidence for a beneficial effect of crenezumab in people with mild AD. The findings were presented at the Alzheimer’s Association International Conference (AAIC) 2014 in Copenhagen, Denmark. Roche will determine next steps for crenezumab after further analysis of the data.

Clinical results to date for crenezumab suggest a favorable risk benefit profile, with positive effects on both cognitive and global functional endpoints, particularly in patients with milder Alzheimer's disease, and a minimal incidence of amyloid related imaging abnormalities.

Prof. Andrea Pfeifer, CEO of AC Immune said: “These very promising crenezumab data show this antibody is one of the best performing therapies tested so far in Phase II for Alzheimer’s disease. The unique combination of its safety profile and proven mechanism-of-action could potentially allow crenezumab to be given to patients at efficacious doses without the side effects that have hampered other therapies.”

https://www.bionity.com/en/news/149199/crenezumab-phase-ii-cognition-data-in-alzheimers-disease-presented.html